Finally, based on the candidate neoepitopes identified in the third step, we developed an efficient scoring model, RefinedNeo, which calculates a refined immunogenicity score reflecting the probability of naturally processed, MHC-presented, and T cell-recognized neopeptide and the actual immunologic effects of a neopeptide in clinical tumor treatment. Here, HLA-C is linked to neoplasm.